Bleximenib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; mixed-lineage leukemia 1; MLL1; myeloid/lymphoid leukemia; histone-lysine N-methyltransferase 2A; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, bleximenib inhibits the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of leukemic cells with either KMT2A alterations such as gene rearrangements (KMT2A-r), duplications, and amplification, or nucleophosmin 1 gene (NPM1) alterations. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.

**Synonyms:** - BLEXIMENIB - JNJ 6617 - JNJ 75276617 - JNJ-6617 - JNJ-75276617 - JNJ6617 - JNJ75276617 - Menin-KMT2A Interaction Inhibitor JNJ-75276617 - Menin-MLL1 Interaction Inhibitor JNJ-75276617